R

Redx Pharma PLC
LSE:REDX

Watchlist Manager
Redx Pharma PLC
LSE:REDX
Watchlist
Price: 15 GBX 31.58% Market Closed
Updated: May 28, 2024

Redx Pharma PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Redx Pharma PLC
Income from Continuing Operations Peer Comparison

Comparables:
GSK
AZN
INDV
HIK
DPH

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
R
Redx Pharma PLC
LSE:REDX
Income from Continuing Operations
-£33.2m
CAGR 3-Years
-53%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Income from Continuing Operations
£4.8B
CAGR 3-Years
-7%
CAGR 5-Years
2%
CAGR 10-Years
-1%
AstraZeneca PLC
LSE:AZN
Income from Continuing Operations
$6.3B
CAGR 3-Years
17%
CAGR 5-Years
23%
CAGR 10-Years
12%
Indivior PLC
LSE:INDV
Income from Continuing Operations
$5m
CAGR 3-Years
-63%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Income from Continuing Operations
$192m
CAGR 3-Years
-24%
CAGR 5-Years
-8%
CAGR 10-Years
-1%
Dechra Pharmaceuticals PLC
LSE:DPH
Income from Continuing Operations
-£27.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Redx Pharma PLC's Income from Continuing Operations?
Income from Continuing Operations
-33.2m GBP

Based on the financial report for Sep 30, 2023, Redx Pharma PLC's Income from Continuing Operations amounts to -33.2m GBP.

What is Redx Pharma PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-30%

Over the last year, the Income from Continuing Operations growth was -84%. The average annual Income from Continuing Operations growth rates for Redx Pharma PLC have been -53% over the past three years , -30% over the past five years .